Drug & Therapeutics Committee NICE Drug Technology Appraisals ratified by D&TC since 2018

These medicines have a positive NICE Technology Appraisal and are listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines

D&TC date NICE TA date Drug name Indication January 2018 November 2017 Aflibercept For treating choroidal neovascularisation (TA486) (recombinant fusion protein) January 2018 November 2017 For treating chronic (TA487) (selective inhibitor of B-cell lymphocytic leukaemia lymphoma-2 (BCL-2))

January 2018 November 2017 Regorafenib For previously treated (TA488) (inhibitor of several protein kinases) unresectable or metastatic gastrointestinal stromal tumours January 2018 November 2017 Vismodegib For treating of adult patients with: symptomatic metastatic basal (TA489) (hedgehog pathway inhibitor) cell carcinoma; locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy. January 2018 November 2017 Nivolumab For treating squamous cell carcinoma of the head and neck after (TA490) (human immunoglobulin G4 platinum-based monoclonal antibody) January 2018 November 2017 Ibrutinib For treating Waldenstrom’s macroglobulinaemia (TA491) (tyrosine kinase inhibitor) January 2018 December 2017 Atezolizumab For untreated locally (TA492) (monoclonal antibody, which binds advanced or metastatic urothelial cancer to the programmed death-1 (PD-1) when is unsuitable receptor) January 2018 December 2017 For treating (TA493) () relapsing–remitting multiple sclerosis March 2018 December 2017 Naltrexone – bupropion Adjunct to a reduced-calorie diet and increased physical activity, for (TA 494) (Centrally acting appetite the management of weight in adult patients (aged 18 and over) suppressants) with an initial BMI of:  30 kg/m2 or more (obese) or

 from 27 kg/m2 to 30 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities (such as type 2 diabetes, dyslipidaemia, or controlled hypertension). Treatment should be stopped after 16 weeks if the patient has not lost at least 5% of their initial body weight. March 2018 December 2017 with an aromatase For previously untreated, hormone (TA 495) inhibitor (selective, small-molecule receptor-positive, HER2-negative, locally inhibitor of cyclindependent advanced or metastatic breast cancer kinases 4 and 6)

March 2018 December 2017 with an aromatase For previously untreated, hormone receptor-positive, HER2- (TA 496) inhibitor negative, locally advanced or metastatic breast cancer March 2018 January 2018 Golimumab For treating non-radiographic axial spondyloarthritis (TA 497) (Cytokine modulator) March 2018 January 2018 Lenvatinib with everolimus For previously (TA 498) treated advanced renal cell carcinoma March 2018 January 2018 Glecaprevir–pibrentasvir (Maviret) For treating chronic hepatitis C (genotypes 1-6) (TA 499) March 2018 January 2018 Ceritinib For untreated ALK-positive non-small-cell lung cancer (TA 500) (tyrosine kinase inhibitor) March 2018 January 2018 Intrabeam radiotherapy system For adjuvant treatment of early breast cancer (TA 501) (mobile irradiation System) March 2018 January 2018 For treating relapsed or (TA 502) Ibrutinib refractory mantle cell lymphoma (tyrosine kinase inhibitor) March 2018 January 2018 Fulvestrant For untreated locally (TA 503) advanced or metastatic oestrogenreceptor (estrogen receptor antagonists) positive breast cancer

March 2018 February 2018 Pirfenidone For treating idiopathic (TA 504) pulmonary fibrosis (Pyridones) March 2018 February 2018 () For treating relapsed or (TA 505) with lenalidomide and refractory multiple myeloma dexamethasone March 2018 February 2018 Lesinurad For treating chronic hyperuricaemia in people with gout (together (TA 506) with a xanthine oxidase inhibitor) (oral selective inhibitor of the URAT1 and OAT4 uric acid (UA)) May 2018 February 2018 Sofosbuvir–velpatasvir–voxilaprevir For treating chronic hepatitis C

(TA 507) May 2018 March 2018 Autologous chondrocyte For treating symptomatic articular cartilage defects of the knee implantation using chondrosphere (TA 508) May 2018 March 2018 Pertuzumab with trastuzumab and For treating HER2-positive breast cancer (TA 509) May 2018 March 2018 Daratumumab monotherapy For treating relapsed and refractory multiple myeloma

(TA 510) (humanised monoclonal antibody that targets the CD38 protein) May 2018 March 2018 Brodalumab For treating moderate to severe plaque psoriasis (TA 511) (recombinant human monoclonal antibody) May 2018 March 2018 Tivozanib For treating advanced renal cell carcinoma

(TA 512) (tyrosine kinase inhibitor) May 2018 March 2018 Obinutuzumab For untreated advanced follicular lymphoma (TA 513) (anti-lymphocyte monoclonal antibody)

May 2018 March 2018 Regorafenib For previously treated advanced hepatocellular carcinoma (TA 514) (inhibitor of several protein kinases) May 2018 March 2018 For treating locally advanced or metastatic breast cancer after 1 (TA 515) (non- dynamics inhibitor) May 2018 March 2018 Cabozantinib For treating medullary thyroid cancer (TA 516) (inhibitor of several protein kinases)

May 2018 April 2018 Avelumab For treating metastatic Merkel cell carcinoma

(TA 517) (monoclonal antibody) May 2018 April 2018 Tocilizumab For treating giant cell arteritis (TA 518) (recombinant, humanized, anti- human interleukin 6 (IL-6) receptor monoclonal antibody) July 2018 April 2018 Pembrolizumab (Keytruda) For the treatment of locally advanced or metastatic urothelial (TA 519) carcinoma in adults who have received prior platinum-containing chemotherapy July 2018 May 2018 Atezolizumab For treating locally advanced or metastatic non-small-cell lung (TA 520) (Tecentriq) cancer (NSCLC) in adults who have had chemotherapy (and targeted treatment if they have an EGFR- or ALK-positive tumour) July 2018 June 2018 Guselkumab For treating plaque psoriasis in adults (TA 521)

July 2018 June 2018 Pembrolizumab For untreated locally advanced or metastatic urothelial carcinoma (TA 522) in adults when cisplatin-containing chemotherapy is unsuitable

July 2018 June 2018 Midostaurin For treating newly diagnosed acute FLT3-mutation-positive myeloid (TA 523) leukaemia with standard and as induction therapy, with high-dose cytarabine as consolidation therapy, and alone after complete response as maintenance therapy July 2018 June 2018 Brentuximab vedotin For treating CD30‑positive Hodgkin lymphoma in adults with (TA 524) relapsed or refractory disease

July 2018 June 2018 Atezolizumab For treating locally advanced or metastatic urothelial carcinoma in (TA 525) adults who have had platinum-containing chemotherapy

July 2018 June 2018 For inducing remission and consolidation in acute promyelocytic (TA 526) leukaemia (characterised by the presence of the t[15;17] translocation or the PML/RAR-alpha gene) in adults September 2018 June 2018 Beta-interferons and glatiramer Evidence-based recommendations for treating multiple sclerosis in (TA527) acetate adults. September 2018 July 2018 For treating relapsed, platinum-sensitive high-grade serous (TA528) epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to the most recent course of platinum-based chemotherapy in adults September 2018 July 2018 Crizotinib For treating ROS1-positive advanced non-small-cell lung cancer (TA529) September 2018 July 2018 Nivolumab For treating locally advanced unresectable or metastatic urothelial (TA 530) cancer after platinum-containing chemotherapy September 2018 July 2018 Pembrolizumab For untreated PD-L1-positive metastatic non-small-cell lung cancer (TA 531) September 2018 July 2018 Cenegermin For the treatment of moderate (persistent epithelial defect) or (TA 532) severe (corneal ulcer) neurotrophic keratitis in adults September 2018 July 2018 Ocrelizumab For the treatment of adult patients with relapsing forms of multiple (TA 533) sclerosis (RMS) with active disease defined by clinical or imaging features September 2018 August 2018 Dupilumab For the treatment of moderate to severe atopic dermatitis in adults (TA534) who are candidates for systemic therapy September 2018 August 2018 Lenvatinib and sorafenib For treating progressive, locally advanced or metastatic (TA 535) differentiated thyroid cancer September 2018 August 2018 Alectinib For untreated anaplastic lymphoma kinase (ALK)-positive advanced (TA 536) non-small-cell lung cancer (NSCLC) in adults September 2018 August 2018 Ixekizumab For treating active psoriatic arthritis in adults (TA 537) September 2018 August 2018 Dinutuximab beta For treating high-risk neuroblastoma (TA 538) August 2018 Lutetium (177Lu) oxodotreotide For 'unresectable or metastatic, progressive, well-differentiated (TA 539) (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP NETs) in adults November 2018 September 2018 Pembrolizumab For treating relapsed or refractory classical Hodgkin lymphoma (TA 540)

November 2018 September 2018 Inotuzumab ozogamicin For treating relapsed or refractory B-cell acute lymphoblastic (TA 541) leukaemia

November 2018 October 2018 Cabozantinib For untreated advanced renal cell carcinoma (TA 542)

November 2018 October 2018 Tofacitinib For treating active psoriatic arthritis after inadequate response to (TA 543) DMARDs

November 2018 October 2018 Dabrafenib with trametinib For adjuvant treatment of resected BRAF V600 mutation-positive (TA 544) melanoma

January 2019 November 2018 Gemtuzumab ozogamicin For untreated acute myeloid leukaemia (TA545) (monoclonal antibody)

January 2019 November 2018 Padeliporfin For untreated localised prostate cancer (TA 546)

January 2019 November 2018 Tofacitinib For moderately to severely active ulcerative colitis (TA 547)

January 2019 December 2018 Vandetanib For treating medullary thyroid cancer (TA 550)

January 2019 December 2018 Lenvatinib For untreated advanced hepatocellular carcinoma (TA 551)

January 2019 December 2018 Liposomal cytarabine-daunorubicin For untreated therapy-related acute myeloid leukaemia or acute (TA 552) myeloid leukaemia with myelodysplasia-related changes in adults

January 2019 December 2018 Pembrolizumab For adjuvant treatment of resected melanoma with high risk of (TA 553) recurrence

January 2019 December 2018 Tisagenlecleucel For treating relapsed or refractory B-cell acute lymphoblastic (TA554) leukaemia in people aged up to 25 years

March 2019 Jan 2019 Regorafenib Previously treated advanced hepatocellular carcinoma (TA555)

March 2019 Jan 2019 Darvadstrocel Complex perianal fistulas in Crohn’s disease (TA 556)

March 2019 Jan 2019 Pembrolizumab untreated, metastatic, non-squamous non-small-cell lung cancer (TA 557) (with and platinum chemotherapy)

March 2019 Jan 2019 Nivolumab Adjuvant treatment of completely resected melanoma with lymph (TA 558) node involvement or metastatic disease

March 2019 Jan 2019 (TA 559) Axicabtagene ciloleucel Option for treating relapsed or refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies, only if the conditions in the managed access agreement are followed. March 2019 Jan 2019 (TA 561) Venetoclax with rituxumab Chronic lymphocytic leukaemia in adults who have had at least 1 previous therapy

March 2019 Jan 2019 (TA562) Encorafenib with binimetinib Unresectable or metastatic BRAF V600 mutation-positive melanoma

March 2019 Jan 2019 (TA563) with aromatase for untreated, hormone receptor-positive, HER2- negative locally inhibitor advanced or metastatic breast cancer

May 2019 March 2019 Benralizumab (Fasenra) Add on therapy for treating severe eosinophilic asthma in adults. (TA 565)

May 2019 March 2019 Cochlear For children and adults with severe to profound deafness (TA 566) Implant

May 2019 March 2019 Tisagenlecleucel Treatment of relapsed or refractory diffuse large B-cell lymphoma (TA 567) after 2 or more systemic therapies (adults) Immunocellular CAR T-cell therapy. Contains the patient's own T cells (a type of white blood cell) that have been modified genetically in the laboratory so that they make a protein called chimeric antigen receptor (CAR)

May 2019 March 2019 (TA Pertuzumab Adjuvant treatment of HER2-positive early stage breast cancer 569) (with trastuzumab)

May 2019 March 2019 (TA Brigatinib Anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell 571) lung cancer previously treated with crizotinib (Adults)

May 2019 March 2019 Ertugliflozin Monotherapy or with metformin for treating type 2 diabetes in (TA572) adults

May 2019 April Daratumumab Previously treated multiple myeloma in adults. (TA573) with ( and dexamethasone)

May 2019 April certolizumab pegol for treating moderate to severe plaque psoriasis in adults. (TA574) (Cimzia)

May 2019 April Tildrakizumab (Ilumetri) moderate to severe plaque psoriasis in adults (TA575)

May 2019 April Brentuximab vedotin (Adcetris) CD30-positive cutaneous T-cell lymphoma in adults (TA577)

July 2019 MAY 2019 Durvalumab (Imfinz) Monotherapy for the treatment of locally advanced, unresectable non- (TA 578) small-cell lung cancer in adults whose tumours express PD-L1 on ≥1% of tumour cells and whose disease has not progressed following platinum- based chemoradiation

July 2019 MAY 2019 Abemaciclib (Verzenios) Treatment of hormone receptor-positive, human epidermal growth factor (TA 579) 2 (HER2)-negative locally advanced or metastatic breast cancer in adults who have had endocrine therapy.

July 2019 MAY 2019 (TA 581) Nivolumab For untreated advanced renal carcinoma (with Ipilimub)

July 2019 JUNE Ertugliflozin (Steglatro) As monotherapy Treatment of type 2 diabetes in adults (TA583) or with metformin and a dipeptidyl peptidase-4 inhibitor

July 2019 JUNE Atezolizumab (Tecentriq, Roche) plus Treatment of metastatic non-squamous non-small-cell lung cancer (TA584) bevacizumab (Avastin, Roche), (NSCLC) in adults: and  who have not had treatment for their metastatic NSCLC before and whose PD-L1 tumour proportion score is between 0% and 49%   Or   when targeted therapy for epidermal growth factor receptor (EGFR)-positive or anaplastic lymphoma kinase (ALK)-positive NSCLC has failed

July 2019 JUNE Ocrelizumab Treatment of early primary progressive multiple sclerosis with imaging (TA585) features characteristic of inflammatory activity in adults

July 2019 JUNE Lenalidomide Treatment of multiple myeloma after 1 treatment with bortezomib (TA586) With dexamethasone

July 2019 JUNE (TA587) Lenalidomide plus dexamethasone For previously untreated multiple myeloma in adults who are not eligible for a stem cell transpla

September 2019 JULY 2019 Nusinersen (Spinraza) Treatment of spinal muscular atrophy (SMA) in children and adults. (TA 588)

September 2019 JULY 2019 Blinatumomab (Blincyto) Treatment of Philadelphia-chromosome-negative CD19-positive B- (TA 589) precursor acute lymphoblastic leukaemia in remission with minimal residual disease activity in adults.

September 2019 JULY 2019 (TA 590) Fluocinolone acetonide intravitreal Treatment of recurrent non-infectious uveitis in adults implant (Iluvien)

September 2019 JULY 2019 Letermovir (Prevymis) Treatment for preventing cytomegalovirus disease after a stem cell (TA 591) transplant.

September 2019 AUGUST 2019 Cemiplimab (Libtayo) For treating locally advanced or metastatic cutaneous squamous cell (TA 592) carcinoma in adults.

September 2019 AUGUST 2019 Ribociclib (Kisqali) (TA 593) Treatment for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy.

Recommended for use within the Cancer Drugs Fund

September 2019 AUGUST 2019 Dacomitinib (Vizimpro) For untreated locally advanced or metastatic epidermal growth factor (TA 595) receptor (EGFR) mutation-positive non-small-cell lung cancer in adults. (1st line treatment)

September 2019 AUGUST 2019 Risankizumab (Skyrizi) For treating moderate to severe plaque psoriasis in adults. (TA 596)

November 2019 AUGUST 2019 Dapagliflozin (Forxiga) Adjunct with Insulin for treating type 1 diabetes not controlled by insulin (TA 597) therapy alone in adults with a body mass index (BMI) of at least 27 kg/m2.

November 2019 AUGUST 2019 (Lynparza) Treatment of BRCA mutation-positive, advanced ovarian, fallopian tube (TA 598) or primary peritoneal cancer that has responded to first-line platinum- based chemotherapy in adults.

November 2019 SEPT 2019 (TA 599) Sodium zirconium cyclosilicate Treatment of hyperkalaemia in adults. (Lokelma)

November 2019 SEPT 2019 Pembrolizumab (Keytruda) with Treatment for adults with untreated metastatic squamous non-small-cell (TA 600) carboplatin and paclitaxel lung cancer.

November 2019 OCT 2019 Xeomin (botulinum neurotoxin type A) For treating chronic sialorrhoea caused by neurological conditions in (TA 604) adults

November 2019 OCT 2019 Lanadelumab For preventing recurrent attacks of hereditary angioedema (TA 606)

November 2019 OCT 2019 (TA 607) Rivaroxaban For preventing atherothrombotic events in people with coronary or peripheral artery disease

Last updated November 2019